The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Open Access
- 24 February 2021
- Vol. 10 (3), 484
- https://doi.org/10.3390/cells10030484
Abstract
Glioblastoma (GBM) is the most lethal type of primary brain cancer. Standard care using chemo- and radio-therapy modestly increases the overall survival of patients; however, recurrence is inevitable, due to treatment resistance and lack of response to targeted therapies. GBM therapy resistance has been attributed to several extrinsic and intrinsic factors which affect the dynamics of tumor evolution and physiology thus creating clinical challenges. Tumor-intrinsic factors such as tumor heterogeneity, hypermutation, altered metabolomics and oncologically activated alternative splicing pathways change the tumor landscape to facilitate therapy failure and tumor progression. Moreover, tumor-extrinsic factors such as hypoxia and an immune-suppressive tumor microenvironment (TME) are the chief causes of immunotherapy failure in GBM. Amid the success of immunotherapy in other cancers, GBM has occurred as a model of resistance, thus focusing current efforts on not only alleviating the immunotolerance but also evading the escape mechanisms of tumor cells to therapy, caused by inter- and intra-tumoral heterogeneity. Here we review the various mechanisms of therapy resistance in GBM, caused by the continuously evolving tumor dynamics as well as the complex TME, which cumulatively contribute to GBM malignancy and therapy failure; in an attempt to understand and identify effective therapies for recurrent GBM.Keywords
Funding Information
- National Cancer Institute (CA221747, CA234799)
- National Institute of Neurological Disorders and Stroke (NS093843, NS095634, NS115403)
- The Lou and Jean Malnati Brain Tumor Institute at Northwestern Medcine (10031379)
This publication has 156 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5AGenes & Development, 2013
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsProceedings of the National Academy of Sciences of the United States of America, 2013
- A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium studyJournal of Neuro-Oncology, 2011
- Acquisition of Temozolomide Chemoresistance in Gliomas Leads to Remodeling of Mitochondrial Electron Transport ChainJournal of Biological Chemistry, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Hypoxia and cancerJournal of Molecular Medicine, 2007
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005